{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:34:32Z","timestamp":1789382072256,"version":"build-2803163510"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","award":["20771"],"award-info":[{"award-number":["20771"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRA_POR\/2011\/23"],"award-info":[{"award-number":["HRA_POR\/2011\/23"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["SFI\/12\/RC\/2273"],"award-info":[{"award-number":["SFI\/12\/RC\/2273"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["201 714"],"award-info":[{"award-number":["201 714"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["FP7\/2007\u20132013"],"award-info":[{"award-number":["FP7\/2007\u20132013"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jad.2013.11.014","type":"journal-article","created":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T21:45:36Z","timestamp":1386625536000},"page":"24-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"special_numbering":"C","title":["A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action"],"prefix":"10.1016","volume":"156","author":[{"given":"Marie","family":"Naughton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia F.","family":"O\u2032Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Cryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Dinan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2013.11.014_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated dose intravenous ketamine for treatment resistant depression","volume":"67","author":"Aan het Rot","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine and depression: where do we go from here?","volume":"72","author":"Aan het Rot","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2013.11.014_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/YCT.0b013e31824f8296","article-title":"Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting","volume":"28","author":"Abdallah","year":"2012","journal-title":"J. ECT"},{"issue":"2","key":"10.1016\/j.jad.2013.11.014_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00213-013-3153-2","article-title":"Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synaptic and mTOR","volume":"230","author":"Akinfiresoye","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jad.2013.11.014_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neulet.2013.04.045","article-title":"Does increasing the ratio of AMPA-to-NMDA receptor medicated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests","volume":"546","author":"Andreasen","year":"2013","journal-title":"Neurosci. Lett."},{"issue":"91","key":"10.1016\/j.jad.2013.11.014_bib6","first-page":"e95","article-title":"NMDA Receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jad.2013.11.014_bib7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.biopsych.2007.02.006","article-title":"Chronic stress decreases cell proliferation in adult cerebral cortex of rat: reversal by antidepressant treatment","volume":"62","author":"Banasr","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.biopsych.2005.10.018","article-title":"Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)\/Kainate receptors by antidepressant drugs","volume":"59","author":"Barbon","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/0022-006X.47.2.343","article-title":"Assessment of suicidal intention: the scale for suicide ideation","volume":"47","author":"Beck","year":"1979","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.jad.2013.11.014_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2013.11.014_bib11","first-page":"1068","article-title":"Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effects of ketamine in mice","volume":"16","author":"Beurel","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1192\/bjp.120.559.679","article-title":"Ketamine (\u201cKetalar\u201d): a safer anaesthetic for ECT","volume":"120","author":"Brewer","year":"1972","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1139\/jpn.0441","article-title":"The role of the hippocampus in the pathophysiology of major depression","volume":"29","author":"Campbell","year":"2004","journal-title":"J. Psychiatr. Neurosci."},{"key":"10.1016\/j.jad.2013.11.014_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pain.2003.07.001","article-title":"Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain; a randomised, double-blind, placebo-controlled, cross-over study","volume":"108","author":"Carr","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.jad.2013.11.014_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1440-1819.2009.01972.x","article-title":"Cystitis associated with chronic ketamine abuse","volume":"63","author":"Chen","year":"2009","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.jad.2013.11.014_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/jps.2600710516","article-title":"Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans","volume":"71","author":"Clemens","year":"1982","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jad.2013.11.014_bib17","series-title":"Intravenous Anaesthesia and Analgesia. Philadelphia: Lea and Febiger","first-page":"99","article-title":"Dissociative anaesthesia","author":"Corrsen","year":"1988"},{"key":"10.1016\/j.jad.2013.11.014_bib18","series-title":"Handbook of Anxiety and Fear","article-title":"The glutamatergic system as a potential therapeutic target for the treatment of anxiety disorders","author":"Cryan","year":"2007"},{"key":"10.1016\/j.jad.2013.11.014_bib19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1126\/science.1194313","article-title":"A glutamate pathway to faster acting antidepressants","volume":"329","author":"Cryan","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jad.2013.11.014_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomised add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2013.11.014_bib21","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0031-6997(24)01394-2","article-title":"The glutamate receptor ion channels","volume":"51","author":"Dingledine","year":"1999","journal-title":"Pharmacol. Rev."},{"issue":"6 Suppl. 4","key":"10.1016\/j.jad.2013.11.014_bib23","first-page":"S233","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jad.2013.11.014_bib24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.biopsych.2009.11.021","article-title":"Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial","volume":"67","author":"Drevets","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2013.11.014_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.npp.1301178","article-title":"The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders","volume":"32","author":"Du","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2013.11.014_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.08.044","article-title":"Signalling pathways underlying the rapid antidepressant actions of ketamine","volume":"62","author":"Duman","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2013.11.014_bib28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4088\/JCP.v62n1106","article-title":"Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo","volume":"62","author":"Entsuah","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib29","doi-asserted-by":"crossref","first-page":"3257e62","DOI":"10.1097\/00001756-200110290-00023","article-title":"Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia","volume":"12","author":"Fatemi","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.jad.2013.11.014_bib30","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1176\/ajp.2006.163.7.1161","article-title":"A comparison of mirtazepine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a Star\u204eD Report","volume":"163","author":"Fava","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-013-3024-x","article-title":"Ketamine elicits sustained antidepressant activity via a serotonin dependant mechanism","volume":"228","author":"Gigliucci","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2013.11.014_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.yct.0000263257.44539.23","article-title":"Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy","volume":"23","author":"Goforth","year":"2007","journal-title":"J. ECT"},{"key":"10.1016\/j.jad.2013.11.014_bib33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1192\/bjp.122.1.123-a","article-title":"Ketamine as an anaesthetic for ECT","volume":"122","author":"Green","year":"1973","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib34","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2011.03.019","article-title":"Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression","volume":"35","author":"Ibrahim","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib35","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmaclogy"},{"issue":"7","key":"10.1016\/j.jad.2013.11.014_bib36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/jpm.2010.9808","article-title":"Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care","volume":"13","author":"Irwin","year":"2010","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.jad.2013.11.014_bib37","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/jpm.2012.0617","article-title":"Daily oral ketamine for treatment of depression and anxiety in patients receiving hospice care: a 28 day open-label proof-of-concept trial","volume":"8","author":"Irwin","year":"2013","journal-title":"J. Palliat. Med."},{"issue":"27","key":"10.1016\/j.jad.2013.11.014_bib500","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1523\/JNEUROSCI.6078-08.2009","article-title":"Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation","volume":"29","author":"Jourdi","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jad.2013.11.014_bib38","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results for the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2013.11.014_bib39","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.93.16.8455","article-title":"A molecular mechanism for the effect of lithium on development","volume":"93","author":"Klein","year":"1996","journal-title":"Proc. Nat. Acad Sci. U.S.A."},{"key":"10.1016\/j.jad.2013.11.014_bib40","first-page":"1186","article-title":"Ketamine: teaching an old drug new tricks","volume":"87","author":"Kohrs","year":"1998","journal-title":"Anaesthesiol. Analgesia"},{"key":"10.1016\/j.jad.2013.11.014_bib41","first-page":"170","article-title":"Ketamine followed by memantine for the treatment of major depression","volume":"42","author":"Kollmar","year":"2008","journal-title":"Aust. N.Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00406-011-0205-7","article-title":"Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study","volume":"261","author":"Kranaster","year":"2011","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2013.11.014_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s002130051049","article-title":"Interactive effects of subanaesthetic ketamine and haloperidol in healthy humans","volume":"145","author":"Krystal","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jad.2013.11.014_bib45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1196\/annals.1300.010","article-title":"NMDA receptor antagonism and the ethanol intoxication signal: form alcoholism risk to pharmacotherapy","volume":"1003","author":"Krystal","year":"2003","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.jad.2013.11.014_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1176\/jnp.15.1.27","article-title":"Comparison of seizure duration, ictal EEG and cognitive effects of ketamine and methohexital anaesthesia with ECT","volume":"15","author":"Krystal","year":"2003","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2013.11.014_bib47","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archpsyc.62.9.985","article-title":"Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function","volume":"62","author":"Krystal","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib48","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","article-title":"Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond","volume":"73","author":"Krystal","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib49","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0006-3223(00)01037-4","article-title":"Long-term outcome of patients who receive ketamine during research","volume":"49","author":"Lahti","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.me.26.020175.001033","article-title":"Ketamine anaesthesia","volume":"26","author":"Lanning","year":"1975","journal-title":"Ann. Rev. Med."},{"issue":"9","key":"10.1016\/j.jad.2013.11.014_bib52","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1017\/S1461145713000485","article-title":"Antidepressant, mood stabilising and precognitive effects of very lose dose sublingual ketamine in refractory unipolar and bipolar depression","volume":"16","author":"Lara","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.jad.2013.11.014_bib53","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1017\/S1461145711000629","article-title":"A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department","volume":"14","author":"Larkin","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2013.11.014_bib54","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0028-3908(00)00194-5","article-title":"Anti-depressant-like actions of an AMPA receptor potentiator (LY392098)","volume":"40","author":"Li","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2013.11.014_bib55","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR dependant synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jad.2013.11.014_bib56","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1073\/pnas.0706679105","article-title":"Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy","volume":"105","author":"Liu","year":"2008","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.jad.2013.11.014_bib58","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/npp.2013.128","article-title":"GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine","volume":"38","author":"Liu","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2013.11.014_bib59","doi-asserted-by":"crossref","first-page":"697e706","DOI":"10.1016\/S0306-4522(02)00652-8","article-title":"Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268","volume":"117","author":"Lorrain","year":"2003","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.jad.2013.11.014_bib60","doi-asserted-by":"crossref","first-page":"e56053","DOI":"10.1371\/journal.pone.0056053","article-title":"Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice","volume":"8","author":"Ma","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2013.11.014_bib61","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.biopsych.2008.06.027","article-title":"Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder","volume":"64","author":"Macqueen","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib501","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0006-3223(03)00117-3","article-title":"Enhancing neuronal plasticity and cellular resilience to develop novel improved therapeutics for difficult to treat depression","volume":"53","author":"Manji","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib63","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.neuropharm.2005.07.006","article-title":"Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment","volume":"49","author":"Martinez-Turrillas","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2013.11.014_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomised, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2013.11.014_bib65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejphar.2007.11.071","article-title":"Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators","volume":"583","author":"McEwen","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jad.2013.11.014_bib66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00124509-200606000-00005","article-title":"Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies","volume":"22","author":"McDaniel","year":"2006","journal-title":"J. ECT"},{"issue":"2\u20133","key":"10.1016\/j.jad.2013.11.014_bib68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-3940(01)02098-5","article-title":"Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes","volume":"310","author":"Mizuta","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jad.2013.11.014_bib69","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0028-3908(93)90055-8","article-title":"Reduction of NMDA induced behaviour after acute and chronic administration of desipramine in mice","volume":"32","author":"Mjellem","year":"1993","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2013.11.014_bib70","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jad.2013.11.014_bib71","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.biopsych.2012.09.006","article-title":"The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine","volume":"73","author":"Monteggia","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.npp.1300342","article-title":"Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers","volume":"29","author":"Morgan","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2013.11.014_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: a review","volume":"107","author":"Morgan","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.jad.2013.11.014_bib74","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/3661","article-title":"Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition","volume":"1","author":"Mott","year":"1998","journal-title":"Nat. Neurosci."},{"issue":"7","key":"10.1016\/j.jad.2013.11.014_bib75","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jpsychires.2013.03.008","article-title":"Ketamine regulates the presynaptic release machinery in the hippocampus","volume":"47","author":"Muller","year":"2013","journal-title":"J. Psychiatr Res."},{"issue":"7","key":"10.1016\/j.jad.2013.11.014_bib76","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jpsychires.2013.02.015","article-title":"Ketamine, magnesium and major depression\u2014from pharmacology to pathophysiology and back","volume":"47","author":"Murch","year":"2013","journal-title":"J. Psychiatr Res."},{"issue":"170","key":"10.1016\/j.jad.2013.11.014_bib77","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two site randomized controlled trial","volume":"2013","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib78","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib79","article-title":"Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response","author":"Murrough","year":"2013","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.jad.2013.11.014_bib80","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.biopsych.2013.01.038","article-title":"Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression","volume":"74","author":"Niciu","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib81","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1176\/ajp.2006.163.9.1519","article-title":"A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a Star\u204eD report","volume":"163","author":"Nierenberg","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib82","first-page":"208","article-title":"Quantifying the speed of symptomatic improvement with electroconvulsive therapy: comparison of alternative statistical methods","volume":"13","author":"Nobler","year":"1997","journal-title":"Convuls. Ther."},{"issue":"8","key":"10.1016\/j.jad.2013.11.014_bib83","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of schedule 1 drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jad.2013.11.014_bib84","series-title":"G Protein-Coupled Receptors. Structure, Signaling, and Physiology","first-page":"321","article-title":"Role of metabotropic glutamate receptors in CNS disorders","author":"O'Connor","year":"2010"},{"key":"10.1016\/j.jad.2013.11.014_bib85","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejphar.2010.02.059","article-title":"Metabotropic glutamate receptor 7: at the interface of cognition and emotion","volume":"639","author":"O'Connor","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jad.2013.11.014_bib86","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neuropharm.2012.05.006","article-title":"Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment","volume":"66","author":"O'Connor","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2013.11.014_bib87","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/YCT.0b013e3181c3b0aa","article-title":"Rapid antidepressant effect of ketamine anaesthesia during electroconvulsive therapy of treatment resistant depression: comparing ketamine and propofol anaesthesia","volume":"26","author":"Okamoto","year":"2010","journal-title":"J. ECT"},{"key":"10.1016\/j.jad.2013.11.014_bib88","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568007043337508","article-title":"AMPA receptor potentiators for the treatment of CNS disorders","volume":"3","author":"O'Neill","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.jad.2013.11.014_bib89","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0306-4522(93)90355-J","article-title":"The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization","volume":"56","author":"Orrego","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.jad.2013.11.014_bib91","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"issue":"10","key":"10.1016\/j.jad.2013.11.014_bib92","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.biopsych.2013.04.027","article-title":"Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats","volume":"74","author":"Parise","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib93","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-005-0177-2","article-title":"The effects of a subanaesthetic dose of ketamine on verbal memory in normal volunteers","volume":"183","author":"Parwani","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jad.2013.11.014_bib94","first-page":"33","article-title":"Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series","volume":"43","author":"Paslakis","year":"2010","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.jad.2013.11.014_bib95","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/15622970701714370","article-title":"Comparison of racemic ketamine and S-ketamine in treatment\u2013resistant major depression: report of two cases","volume":"10","author":"Paul","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib96","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-3565(25)38715-X","article-title":"Adaptation of the N-methyl-d-aspartate receptor complex following chronic antidepressant treatments","volume":"269","author":"Paul","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2013.11.014_bib97","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00213-007-0706-2","article-title":"Yale ketamine study group. Psychiatric safety of ketamine in psychopharmacology research","volume":"192","author":"Perry","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jad.2013.11.014_bib98","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1176\/ajp.161.10.1776","article-title":"Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism","volume":"161","author":"Petrakis","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib99","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","article-title":"Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist","volume":"65","author":"Phelps","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2013.11.014_bib101","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2013.11.014_bib102","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.biopsych.2009.04.029","article-title":"Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression","volume":"66","author":"Price","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib104","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00001503-200008000-00011","article-title":"Ketamine: a new look at an old drug","volume":"13","author":"Raeder","year":"2000","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.jad.2013.11.014_bib105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF03011442","article-title":"Ketamine: an update on the first twenty-five years of clinical experience","volume":"36","author":"Reich","year":"1989","journal-title":"Can. J. Anaesth"},{"key":"10.1016\/j.jad.2013.11.014_bib106","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\u204eD report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib107","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","article-title":"Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression","volume":"354","author":"Rush","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2013.11.014_bib108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1176\/ajp.2007.164.2.201","article-title":"Star\u204eD: what have we learned?","volume":"164","author":"Rush","year":"2006","journal-title":"Am. J. Psychol."},{"key":"10.1016\/j.jad.2013.11.014_bib109","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrd2462","article-title":"Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders","volume":"7","author":"Sanacora","year":"2008","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.jad.2013.11.014_bib110","doi-asserted-by":"crossref","first-page":"133e43","DOI":"10.1111\/j.1399-5618.2006.00300.x","article-title":"Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder","volume":"8","author":"Scarr","year":"2006","journal-title":"Bipolar Dis."},{"key":"10.1016\/j.jad.2013.11.014_bib111","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archpsyc.65.7.826","article-title":"Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behaviour","volume":"65","author":"Schumann","year":"2008","journal-title":"Arch. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2013.11.014_bib112","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jcph.122","article-title":"Repeated S-ketamine infusions in therapy resistant depression: a case series","volume":"53","author":"Segmiller","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2013.11.014_bib113","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.brainres.2009.03.062","article-title":"Stress-induced dendritic remodeling in the medial prefrontal cortex: effects of circuit, hormones and rest","volume":"2009","author":"Shansky","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.jad.2013.11.014_bib114","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4161\/cc.8.23.10070","article-title":"Targeting mTOR globally in cancer: thinking beyond rapamycin","volume":"8","author":"Shor","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jad.2013.11.014_bib115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-979537","article-title":"Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression","volume":"29","author":"Skolnick","year":"1996","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib116","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1006\/phrs.2000.0806","article-title":"Current perspectives on the development of non-biogenic amine-based antidepressants","volume":"43","author":"Skolnick","year":"2001","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jad.2013.11.014_bib117","doi-asserted-by":"crossref","first-page":"509e47","DOI":"10.1146\/annurev.neuro.26.041002.131412","article-title":"The synaptic vesicle cycle","volume":"27","author":"S\u00fcdhof","year":"2004","journal-title":"Ann. Rev. Neurosci."},{"key":"10.1016\/j.jad.2013.11.014_bib118","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1073\/pnas.052712799","article-title":"Involvement of striatal and extrastriatal DARPP-32 in biochemical effects of fluoxetine (Prozac)","volume":"99","author":"Svenningsson","year":"2002","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jad.2013.11.014_bib119","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00221-005-0228-2","article-title":"Changes in AMPA subunit expression in the mouse brain after chronic treatment with the antidepressant maprotiline: a link between noradrenergic and glutamatergic function?","volume":"170","author":"Tan","year":"2006","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.jad.2013.11.014_bib120","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4088\/JCP.v66n0803","article-title":"Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomised controlled trials","volume":"66","author":"Thase","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib121","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuroscience.2012.03.052","article-title":"Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA\/NMDA receptor density ratio in female Wistar-Kyoto rats","volume":"213","author":"Tizabi","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.jad.2013.11.014_bib122","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication augmentation after the failure of SSRIs for depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jad.2013.11.014_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jad.2013.11.014_bib125","series-title":"The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging: A Task Force Report of the American Psychiatric Association","author":"Weiner","year":"2001"},{"key":"10.1016\/j.jad.2013.11.014_bib126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00000542-198202000-00007","article-title":"Ketamine\u2014its pharmacology and therapeutic uses","volume":"56","author":"White","year":"1982","journal-title":"Anaesthesiology"},{"key":"10.1016\/j.jad.2013.11.014_bib127","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000087097","article-title":"Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS","volume":"52","author":"Wilner","year":"2005","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jad.2013.11.014_bib128","first-page":"53","article-title":"Dilated common bile ducts mimicking choledochal cysts in ketamine abusers","volume":"15","author":"Wong","year":"2009","journal-title":"Hong Kong Med. J."},{"issue":"5","key":"10.1016\/j.jad.2013.11.014_bib129","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/jpm.2010.0525","article-title":"Be prudent of ketamine in treating resistant depression in patients with cancer","volume":"14","author":"Yang","year":"2011","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.jad.2013.11.014_bib130","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-d-aspartate antagonist in treatment resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib131","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","article-title":"A double-blind, placebo-controlled study of memantine in the treatment of major depression","volume":"163","author":"Zarate","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib132","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.expneurol.2008.01.011","article-title":"The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases","volume":"211","author":"Zarate","year":"2008","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.jad.2013.11.014_bib133","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/10673229.2010.511059","article-title":"Glutamatergic modulators: the future for treating mood disorders?","volume":"18","author":"Zarate","year":"2010","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib134","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine's antidepressant efficacy in bipolar depression: a randomised controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2013.11.014_bib135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","article-title":"A randomised trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression","volume":"74","author":"Zarate","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib136","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.biopsych.2012.11.031","article-title":"Human biomarkers of rapid antidepressant effects","volume":"73","author":"Zarate","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2013.11.014_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/mp.2013.87","article-title":"Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties","author":"Zunszain","year":"2013","journal-title":"Mol. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032713008252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032713008252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:12:37Z","timestamp":1759021957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032713008252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":132,"alternative-id":["S0165032713008252"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2013.11.014","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2013.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}